BioDelivery Sciences International Stock Forecast, Price & News

5 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for BioDelivery Sciences International in the last year. There are currently 1 hold rating and 4 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" BioDelivery Sciences International stock.
View analyst ratings for BioDelivery Sciences International or view top-rated stocks.

Wall Street analysts have given BioDelivery Sciences International a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but BioDelivery Sciences International wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

BioDelivery Sciences International is scheduled to release its next quarterly earnings announcement on Thursday, May 6th 2021.
View our earnings forecast for BioDelivery Sciences International.

BioDelivery Sciences International, Inc. (NASDAQ:BDSI) announced its quarterly earnings results on Tuesday, March, 9th. The specialty pharmaceutical company reported $0.10 EPS for the quarter, topping the Zacks' consensus estimate of $0.06 by $0.04. The specialty pharmaceutical company earned $42.17 million during the quarter, compared to the consensus estimate of $38.75 million. BioDelivery Sciences International had a trailing twelve-month return on equity of 25.04% and a net margin of 10.16%.
View BioDelivery Sciences International's earnings history.

BioDelivery Sciences International's stock was trading at $3.96 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, BDSI shares have decreased by 13.6% and is now trading at $3.42.
View which stocks have been most impacted by COVID-19.

BioDelivery Sciences International updated its FY 2021 Pre-Market earnings guidance on Wednesday, March, 10th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $170-180 million, compared to the consensus revenue estimate of $190.23 million.

5 analysts have issued 12 month target prices for BioDelivery Sciences International's stock. Their forecasts range from $5.50 to $9.25. On average, they expect BioDelivery Sciences International's stock price to reach $8.15 in the next year. This suggests a possible upside of 138.3% from the stock's current price.
View analysts' price targets for BioDelivery Sciences International or view top-rated stocks among Wall Street analysts.

Some companies that are related to BioDelivery Sciences International include Johnson & Johnson (JNJ), Pfizer (PFE), Merck & Co., Inc. (MRK), AbbVie (ABBV), Eli Lilly and (LLY), Bristol-Myers Squibb (BMY), Zoetis (ZTS), Royalty Pharma (RPRX), Horizon Therapeutics Public (HZNP), Jazz Pharmaceuticals (JAZZ), Perrigo (PRGO), Nektar Therapeutics (NKTR), Pacira BioSciences (PCRX), Corcept Therapeutics (CORT) and Supernus Pharmaceuticals (SUPN).
View all of BDSI's competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other BioDelivery Sciences International investors own include TG Therapeutics (TGTX), Eldorado Gold (EGO), NVIDIA (NVDA), Inovio Pharmaceuticals (INO), Synergy Pharmaceuticals (SGYP), JD.com (JD), Baidu (BIDU), ACADIA Pharmaceuticals (ACAD), Advanced Micro Devices (AMD) and Alibaba Group (BABA).

BioDelivery Sciences International trades on the NASDAQ under the ticker symbol "BDSI."

BioDelivery Sciences International's stock is owned by a variety of retail and institutional investors. Top institutional investors include NEXT Financial Group Inc (0.16%) and HighPoint Advisor Group LLC (0.10%). Company insiders that own BioDelivery Sciences International stock include Francis E Odonnell Jr, Healthcare Master Fun Broadfin, Herm Cukier, James Vollins, Jeffrey Allen Bailey, Mark A Sirgo, Mary Theresa Coelho, Scott M Plesha, Thomas B Smith and W Mark Watson.
View institutional ownership trends for BioDelivery Sciences International.

BDSI stock was sold by a variety of institutional investors in the last quarter, including NEXT Financial Group Inc. Company insiders that have sold BioDelivery Sciences International company stock in the last year include Francis E Odonnell Jr, James Vollins, Jeffrey Allen Bailey, Mark A Sirgo, Mary Theresa Coelho, and W Mark Watson.
View insider buying and selling activity for BioDelivery Sciences International or view top insider-selling stocks.

BDSI stock was acquired by a variety of institutional investors in the last quarter, including HighPoint Advisor Group LLC.
View insider buying and selling activity for BioDelivery Sciences International or or view top insider-buying stocks.

Shares of BDSI can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of BDSI stock can currently be purchased for approximately $3.42.

BioDelivery Sciences International has a market capitalization of $344.95 million and generates $111.39 million in revenue each year. The specialty pharmaceutical company earns $-15,310,000.00 in net income (profit) each year or $0.10 on an earnings per share basis.

BioDelivery Sciences International employs 176 workers across the globe.

The official website for BioDelivery Sciences International is www.bdsi.com.

BioDelivery Sciences International is headquartered at 4131 PARKLAKE AVENUE SUITE 225, RALEIGH NC, 27612.

BioDelivery Sciences International's mailing address is 4131 PARKLAKE AVENUE SUITE 225, RALEIGH NC, 27612. The specialty pharmaceutical company can be reached via phone at 919-582-9050 or via email at [email protected]